Actively Recruiting
Exploring Safety, Tolerability, and Effectiveness of Oral LT-002-158 Tablets in Chinese Adults With Moderate-to-Severe Hidradenitis Suppurativa
Led by Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. · Updated on 2026-08-27
12
Participants Needed
1
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase IcII clinical trial to study the safety, tolerability, and effectiveness of LT-002-158 tablets in Chinese adults with moderate-to-severe hidradenitis suppurativa HS, a chronic skin condition. The Phase Ic portion is an open-label, single-arm study focused on safety and tolerability, while the Phase II portion is a randomized, double-blind, placebo-controlled trial followed by an open-label extension to assess therapeutic effects. Participants will receive LT-002-158 tablets orally once daily. The study includes two parts the initial Phase Ic safety evaluation and the Phase II randomized comparison with placebo, followed by an extension where all participants may receive the study drug. Treatments are given over a period of up to 42 days, with close monitoring of drug levels in the blood. Throughout the study, participants will undergo assessments including monitoring for adverse events, blood tests to measure drug concentration, and clinical evaluations of their skin condition. They will complete diaries and follow protocol requirements under investigator supervision. Safety and efficacy data will be collected up to 42 days, with the entire study lasting until the end of 2028.
CONDITIONS
Brief Title
A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Patients With Hidradenitis Suppurativa
Research Team
J
Juan Xu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here